Pozen (POZN): Q1 EPS of -$0.28 in-line. Revenue of $1.29M (-71.1% Y/Y) in-line. Shares -0.9%...


Pozen (POZN): Q1 EPS of -$0.28 in-line. Revenue of $1.29M (-71.1% Y/Y) in-line. Shares -0.9% premarket. (PR)
From other sites
Comments (1)
  • Rambowillie
    , contributor
    Comment (1) | Send Message
     
    POZEN should have known to submit NDA data on the 81 mg formulation. This would have allowed FDA to give positive guidance
    1 May 2012, 09:02 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs